Ephedrine Aguettant 30mg/Ml Injection
Ephedrine Hydrochloride
30mg/ml
LABORATOIRE AGUETTANT
| Pack size | 1ml Ampoule x 10 |
|---|---|
| Dispensing mode | POM |
| Source | FRANCE |
| Agent | PHARMALINK |
| Retail Price | 207.50 AED |
Available as:
Indications
Ephedrine Aguettant 30mg/Ml Injection is used for:
Bronchial asthma, Hypotension, Diabetic neuropathic oedema
Adult Dose
Oral
Acute bronchospasm
Adult: As ephedrine HCl: 15-60 mg tid. Max: 150 mg/day.
Diabetic neuropathic oedema
30-60 mg 3 times/day.
Elderly: Initial: 50% of adult dose.
Parenteral
Reversal of spinal or epidural anaesthesia-induced hypotension
Adult: As ephedrine HCl: 3-6 mg by slow IV inj every 3-4 min as required. Max total dose: 30 mg.
Elderly: Same as adult dose.
Child Dose
Oral
Acute bronchospasm
Child: As ephedrine HCl:
1-5 yr 15 mg tid;
6-12 yr 30 mg tid;
>12 yr Same as adult dose.
Parenteral
Reversal of spinal or epidural anaesthesia-induced hypotension
Child: 0.5 mg/kg or 16.7 mg/m2 4-6 hrly by SC or IM inj or
alternatively, 0.75 mg/kg or 25 mg/m2 4 times daily by SC or IV inj.
Renal Dose
Administration
May be taken with or without food.
IV Preparation
Must be diluted before administration as an IV bolus to 5 mg/mL by withdrawing 50 mg (1 mL) dilute with 9 mL 0.9% NaCl or D5W
Contra Indications
Hypersensitivity. Hypertension, thyrotoxicosis, BPH. Lactation.
Precautions
Ischaemic heart disease, hyperthyroidism, diabetes mellitus, hypertension, angle-closure glaucoma, renal impairment; prostatic enlargement; pregnancy, elderly.
Lactation
Unknown if excreted in breast milk
Pregnancy-Lactation
Pregnancy
Ephedrine crosses the placenta; used at deliver for prevention and/or treatment of maternal hypotension associated with spinal anesthesia
Fetal/neonatal adverse reactions
Cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature
These reports describe umbilical artery pH of ?7.2 at the time of delivery
Monitor newborn for signs and symptoms of metabolic acidosis
Monitoring of infant’s acid-base status is warranted to ensure that an episode of acidosis is acute and reversible
Lactation
Unknown if excreted in breast milk
Interactions
Reduces antihypertensive effect of bethanidine and guanethidine. May increase clearance of dexamethasone. Increased incidence of adverse effects when used with theophylline.
Potentially Fatal: Severe HTN when combined with MAOIs or withi 2 wk of discontinuance of MAOI treatment. Increased risk of arrhythmias with cardiac glycosides, quinidine or tricyclic antidepressants. Increased vasoconstriction or pressor effects with ergot alkaloids or oxytocin.
Adverse Effects
Side effects of Ephedrine Hydrochloride :
Gastrointestinal disorders: Nausea, vomiting
Cardiac disorders: Tachycardia, palpitations (thumping heart), reactive hypertension, bradycardia, ventricular ectopics, heart rhythm/rate variability
Nervous system disorders: Dizziness
Psychiatric disorders: Restlessness
Potentially Fatal: Delusions, hallucinations. Seen with hypersensitivity and overdosage. Acute CNS and CVS stimulation presenting as vomiting, fever, hypertension, psychosis. Cardiac arrhythmias.
Mechanism of Action
Ephedrine has both alpha- and beta-adrenergic acitivity with pronounced stimulating effects on the CNS. It increases cardiac output, induces peripheral vasoconstriction, bronchodilation, reduces intestinal tone and motility, and relaxes the bladder while contracting the sphincter muscle. It also has stimulant action on the resp center and dilates the pupil witho affecting light reflexes.
Note
Ephedrine Aguettant 30mg/Ml 30mg/ml Injection manufactured by LABORATOIRE AGUETTANT. Its generic name is Ephedrine Hydrochloride. Ephedrine Aguettant 30mg/Ml is availble in United Arab Emirates.
Farmaco UAE drug index information on Ephedrine Aguettant 30mg/Ml Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.